Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects/Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Pulmonary tuberculosis lung TB,lung tuberculosis,pulmonary TB,pulmonary tuberculosis,Tuberculosis, Pulmonary,Pulmonary tuberculosis
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- ulcerative colitis patients with non-latent tuberculosis (C0)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- ulcerative colitis patients with latent tuberculosis infection (AB0)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- ulcerative colitis patients with latent tuberculosis infection
- Group 0 sample size Number of subjects in the control (unexposed) group
- 9
- Group 1 sample size Number of subjects in the case (exposed) group
- 12
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- decreased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
Signature 1
Source: Figure 2G
Description: Impact of LTBI on the intestinal microbiota of patients with UC. LEfSe analysis highlights the enriched microbial taxa in non-LTBI (Enterobacteriaceae) and LTBI (Streptococcaceae, Sutterellaceae, Burkholderiales) groups. LDA analysis shows the impact of specific taxa on group differences (Enterobacteriaceae in non-LTBI; Sutterellaceae in LTBI).
Abundance in Group 1: increased abundance in ulcerative colitis patients with latent tuberculosis infection (AB0)
| NCBI | Quality Control | Links |
|---|---|---|
| Streptococcus | ||
| Streptococcaceae | ||
| Parasutterella | ||
| Burkholderiales | ||
| Sutterellaceae |
Revision editor(s): Nuerteye
Signature 2
Source: Figure 2G-H
Description: Impact of LTBI on the intestinal microbiota of patients with UC. LEfSe analysis highlights the enriched microbial taxa in non-LTBI (Enterobacteriaceae) and LTBI (Streptococcaceae, Sutterellaceae, Burkholderiales) groups. LDA analysis shows the impact of specific taxa on group differences (Enterobacteriaceae in non-LTBI; Sutterellaceae in LTBI).
Abundance in Group 1: decreased abundance in ulcerative colitis patients with latent tuberculosis infection (AB0)
Revision editor(s): Nuerteye
